中滙集團(00382.HK)授出不超183.31萬份購股權及授出33.78萬股獎勵股份
格隆匯 4 月 29日丨中滙集團(00382.HK)宣佈,於2021年4月29日,公司向公司於2019年6月6日採納的購股權計劃項下合資格的合共6名參與者授出購股權,其附有權利可根據購股權計劃認購合共最多183.31萬股每股0.01美元的股份,每股行使價為8.592港元。
於2021年4月29日,公司亦根據公司於2019年6月6日採納的股份獎勵計劃(不時修訂或修改),授出337,808股獎勵股份(均為現有股份)予合共6名承授人。獎勵股份分別由公司就關連人士及非關連人士設立的信託管理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.